{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.8","upperLimit":"30.9","value":"19.4"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"37.3","value":"21.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"ORR was defined as percentage of participants with objective response (OR) of complete response (CR) and partial response (PR) based on irRECIST. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \\< 10 mm). All target lesions must be assessed. PR was defined as \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. All target lesions must be assessed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG000","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG001","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"NUMBER","populationDescription":"Analysis population included all the randomized participants who received at least 1 dose of study medication, had measurable disease baseline assessment (within 28 days prior to study entry) and at least 1 post baseline assessment or disease progression, global deterioration of health status, or death.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment in Part 2 (maximum of 851 days)","title":"Objective Response Rate (ORR) Based on Immune Related RECIST (irRECIST) - Part 2","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}